Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 16, issue 6, 2018

Potential Impact of Sweetener Input Tax on Public Health pp. 749-751

Prithviraj Lakkakula

Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry pp. 753-763

William V. Padula, Jeromie Ballreich and Gerard F. Anderson

Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review pp. 765-778

Jamison Pike and Scott D. Grosse

SecurAcath for Securing Peripherally Inserted Central Catheters: A NICE Medical Technology Guidance pp. 779-791

Tom Macmillan, Mark Pennington, Jennifer A. Summers, Kate Goddard, Darshan Zala, Naomi Herz, Janet L. Peacock, Stephen Keevil and Anastasia Chalkidou

Level of Evidence in Economic Evaluations of Left Atrial Appendage Closure Devices: A Systematic Review pp. 793-802

Etienne Nédellec, Judith Pineau, Patrice Prognon and Nicolas Martelli

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates pp. 803-817

Jaime Espin, Michael Schlander, Brian Godman, Pippa Anderson, Jorge Mestre-Ferrandiz, Isabelle Borget, Adam Hutchings, Steven Flostrand, Adam Parnaby and Claudio Jommi

Use of Expert Judgement Across NICE Guidance-Making Programmes: A Review of Current Processes and Suitability of Existing Tools to Support the Use of Expert Elicitation pp. 819-836

Alison Peel, Michelle Jenks, Moni Choudhury, Rosemary Lovett, Juan Carlos Rejon-Parrilla, Andrew Sims and Joyce Craig

Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran pp. 837-846

Kamran Bagheri Lankarani, Sulmaz Ghahramani, Najmeh Moradi, Hadi Raeisi Shahraki, Farhad Lotfi and Behnam Honarvar

Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018–2040 pp. 847-857

Scott A. McDonald, Amirah Azzeri, Fatiha Hana Shabaruddin, Maznah Dahlui, Soek S. Tan, Adeeba Kamarulzaman and Rosmawati Mohamed

Effects of the ACA on Preventive Care Disparities pp. 859-869

Cagdas Agirdas and Jordan G. Holding

Estimation of the Direct Cost of Poliomyelitis Rehabilitation Treatment to Pakistani Patients: A 53-Year Retrospective Study pp. 871-888

Atta Abbas Naqvi, Syed Baqir Shyum Naqvi, Fatima Zehra, Ashutosh Kumar Verma, Saman Usmani, Sehrish Badar, Rizwan Ahmad and Niyaz Ahmad

Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model pp. 889-899

Katherine M. Prioli, Julie Katz Karp, Nina M. Lyons, Vera Chrebtow, Jay H. Herman and Laura T. Pizzi

Volume 16, issue 5, 2018

Gun Policy in the United States: Evidence-Based Strategies to Reduce Gun Violence pp. 579-581

Cassandra Crifasi

Opportunities for Use of Blockchain Technology in Medicine pp. 583-590

Igor Radanović and Robert Likić

Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage pp. 591-607

Nikolaos Maniadakis, Anke-Peggy Holtorf, José Otávio Corrêa, Fotini Gialama and Kalman Wijaya

The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017 pp. 609-632

Marcia Reinhart, Lauren M. Scarpati, Noam Y. Kirson, Cody Patton, Nina Shak and Jennifer G. Erensen

Economic Evaluations of Guideline-Based Care for Chronic Wounds: a Systematic Review pp. 633-651

Qinglu Cheng, Nicholas Graves and Rosana E. Pacella

The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review pp. 653-660

Gerard T. Vondeling, Qi Cao, Maarten J. Postma and Mark H. Rozenbaum

The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience pp. 661-674

Thathya V. Ariyaratne, Zanfina Ademi, Molla Huq, Franklin Rosenfeldt, Stephen J. Duffy, Bonny Parkinson, Cheng-Hon Yap, Julian Smith, Baki Billah, Bryan P. Yan, Angela L. Brennan, Lavinia Tran and Christopher M. Reid

Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes pp. 675-684

Megha Bansal, Mona Shah, Brian Reilly, Susan Willman, Max Gill and Francine R. Kaufman

Development of Conversion Functions Mapping the FACT-B Total Score to the EQ-5D-5L Utility Value by Three Linking Methods and Comparison with the Ordinary Least Square Method pp. 685-695

Chun Fan Lee, Raymond Ng, Nan Luo and Yin Bun Cheung

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil pp. 697-709

Wallace Breno Barbosa, Juliana de Oliveira Costa, Lívia Lovato Pires Lemos, Rosângela Maria Gomes, Helian Nunes Oliveira, Cristina Mariano Ruas, Francisco de Assis Acurcio, Corrado Barbui, Marion Bennie, Brian Godman and Augusto Afonso Guerra

Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy pp. 711-722

Matteo Ruggeri, Federica Romano, Michele Basile, Silvia Coretti, Francesca Romana Rolli, Carlo Drago and Americo Cicchetti

Integrating Qualitative Techniques in Model Development: A Case Study Using the Framework Approach pp. 723-733

Samuel N. Frempong, Clare Davenport, Andrew J. Sutton, Justice Nonvignon and Pelham Barton

The Choice of Transcatheter Aortic Valve Implementation (TAVI): Do Patient Co-morbidity and Hospital Ownership Type Matter? pp. 735-744

Udo Schneider, Andreas Schmid, Roland Linder, Dirk Horenkamp-Sonntag and Frank Verheyen

Volume 16, issue 4, 2018

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties pp. 429-432

Rumona Dickson, Angela Boland, Rui Duarte, Eleanor Kotas, Nerys Woolacott, Robert Hodgson, Rob Riemsma, Sabine Grimm, Bram Ramaekers, Manuela Joore, Nasuh Büyükkaramikli, Eva Kaltenthaler, Matt Stevenson, Abdullah Pandor, Steve Edwards, Martin Hoyle, Jonathan Shepherd, Xavier Armoiry and Miriam Brazzelli

The Case for a Private Healthcare Insurance Monopoly pp. 433-443

Paul E. Orzechowski

The Memokath-051 Stent for the Treatment of Ureteric Obstruction: A NICE Medical Technology Guidance pp. 445-464

Emily Eaton Turner, Michelle Jenks, Rachael McCool, Chris Marshall, Liesl Millar, Hannah Wood, Alison Peel, Joyce Craig and Andrew J Sims

Efficiency Measurement in Health Facilities: A Systematic Review in Low- and Middle-Income Countries pp. 465-480

Firdaus Hafidz, Tim Ensor and Sandy Tubeuf

Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder pp. 481-493

Tracy Yuen, Melissa T. Carter, Peter Szatmari and Wendy J. Ungar

Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia pp. 495-502

Barbara de Graaff, Kwang Chien Yee, Philip Clarke and Andrew Palmer

Inference Procedures to Quantify the Efficiency–Equality Trade-Off in Health from Stated Preferences: A Case Study in Portugal pp. 503-513

Micaela Pinho and Anabela Botelho

Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work pp. 515-525

Gerard Harty, James Jarrett and Mireia Jofre-Bonet

Cost-Effectiveness Analysis of Intracapsular Tonsillectomy and Total Tonsillectomy for Pediatric Obstructive Sleep Apnea pp. 527-535

Kenneth Bagwell, Xiao Wu, Eric D. Baum and Ajay Malhotra

Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert® MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis pp. 537-548

Sarah Wood Pallas, Marissa Courey, Chhaily Hy, Wm. Perry Killam, Dora Warren and Brittany Moore

Sugar-Sweetened Beverage Demand and Tax Simulation for Federal Food Assistance Participants: A Case of Two New England States pp. 549-558

Theepakorn Jithitikulchai and Tatiana Andreyeva

Public’s Willingness to Pay Towards a Medical Device for Detecting Foot Ulceration in People with Diabetes pp. 559-567

Fan Yang, Brenda Gannon and Andrew Weightman

Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway pp. 569-577

Fredrik Salvesen Haukaas, Audun Ohna and Tania Krivasi

Volume 16, issue 3, 2018

Pricing of HPV Vaccines in Europe: Back to the Future? pp. 275-277

Livio Garattini and Anna Padula

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching pp. 279-288

Don Husereau, Brian Feagan and Carl Selya-Hammer

Individual and Institutional Corruption in European and US Healthcare: Overview and Link of Various Corruption Typologies pp. 289-302

Margit Sommersguter-Reichmann, Claudia Wild, Adolf Stepan, Gerhard Reichmann and Andrea Fried

Economic Studies on Non-Communicable Diseases and Injuries in India: A Systematic Review pp. 303-315

Indrani Gupta and Arjun Roy

Long-Term Costs and Health Consequences of Issuing Shorter Duration Prescriptions for Patients with Chronic Health Conditions in the English NHS pp. 317-330

Adam Martin, Rupert Payne and Edward CF Wilson

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand pp. 331-345

Lijoy Varghese, Louise Talbot, Andrea Govender, Xu-Hao Zhang and Bruce A. Mungall

Spillover Effects of Long-Term Disabilities on Close Family Members pp. 347-355

Diana Pacheco Barzallo

Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation pp. 357-366

William J. Valentine, Kate Brunt, Kristina S. Boye and Richard F. Pollock

Out of Pocket Costs and Health Insurance Take-Up Rates pp. 367-380

Vasilios D. Kosteas and Francesco Renna

Understanding Treatment Effect Estimates When Treatment Effects Are Heterogeneous for More Than One Outcome pp. 381-393

John M. Brooks, Cole G. Chapman and Mary C. Schroeder

Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia pp. 395-406

Ka Keat Lim, Sook Yee Yoon, Nur Aishah Mohd Taib, Fatiha Hana Shabaruddin, Maznah Dahlui, Yin Ling Woo, Meow Keong Thong, Soo Hwang Teo and Nathorn Chaiyakunapruk

Does €1 Per Prescription Make a Difference? Impact of a Capped Low-Intensity Pharmaceutical Co-Payment pp. 407-414

Pilar Garcia-Gomez, Toni Mora and Jaume Puig-Junoy

Cost-Consequence Analysis Alongside a Randomised Controlled Trial of Hospital Versus Telephone Follow-Up after Treatment for Endometrial Cancer pp. 415-427

Padraig Dixon, Kinta Beaver, Susan Williamson, Chris Sutton, Pierre Martin-Hirsch and William Hollingworth

Volume 16, issue 2, 2018

Does MCDA Trump CEA? pp. 147-151

Carlos Campillo-Artero, Jaume Puig-Junoy and Anthony Culyer

Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia pp. 153-156

David Caldicott, Justin Sinclair, Lynnaire Sheridan and Simon Eckermann

Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations pp. 157-165

Ulf Persson and J. M. Norlin

A Scoping Review of Economic Evaluations Alongside Randomised Controlled Trials of Home Monitoring in Chronic Disease Management pp. 167-176

Kristian Kidholm and Mie Borch Dahl Kristensen

ENDURALIFE-Powered Cardiac Resynchronisation Therapy Defibrillator Devices for Treating Heart Failure: A NICE Medical Technology Guidance pp. 177-186

James Michael Evans, Andrew Cleves, Helen Morgan, Liesl Millar and Grace Carolan-Rees

Involving Members of the Public in Health Economics Research: Insights from Selecting Health States for Valuation to Estimate Quality-Adjusted Life-Year (QALY) Weights pp. 187-194

Elizabeth Goodwin, Kate Boddy, Lynn Tatnell and Annie Hawton

The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada pp. 195-205

Christiaan H. Righolt, Gurpreet Pabla and Salaheddin M. Mahmud

Rich and Well Educated: Are These Requirements Necessary to Claim Healthcare Tax Credits in Italy? pp. 207-217

Elenka Brenna

The Determinants of Household Out-of-Pocket (OOP) Medical Expenditure in Rural Bangladesh pp. 219-234

Shamsul Arifeen Khan Mamun, Rasheda Khanam and Mohammad Mafizur Rahman

A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia pp. 235-242

Caroline G. Watts, Sally Wortley, Sarah Norris, Scott W. Menzies, Pascale Guitera, Lisa Askie, Graham J. Mann, Rachael L. Morton and Anne E. Cust

Cost of Illness for Five Major Foodborne Illnesses and Sequelae in Sweden pp. 243-257

Kristian Sundström

Investigating the Willingness to Pay for a Contributory National Health Insurance Scheme in Saudi Arabia: A Cross-sectional Stated Preference Approach pp. 259-271

Mohammed Khaled Al-Hanawi, Kirit Vaidya, Omar Alsharqi and Obinna Onwujekwe

Correction to: A Scoping Review of Economic Evaluations Alongside Randomised Controlled Trials of Home Monitoring in Chronic Disease Management pp. 273-273

Kristian Kidholm and Mie Borch Dahl Kristensen

Volume 16, issue 1, 2018

Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion? pp. 1-4

Livio Garattini and Anna Padula

Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions pp. 5-14

Carlos King Ho Wong, Olivia Wu and Bernard M. Y. Cheung

A Systematic Review of Cost-of-Illness Studies of Multimorbidity pp. 15-29

Lili Wang, Lei Si, Fiona Cocker, Andrew J. Palmer and Kristy Sanderson

Private Health Insurance Incentives in Australia: In Search of Cost-Effective Adjustments pp. 31-41

P. Marcin Sowa, Sam Kault, Joshua Byrnes, Shu-Kay Ng, Tracy Comans and Paul Scuffham

Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis pp. 43-54

Kathryn Schnippel, Cynthia Firnhaber, Francesca Conradie, Norbert Ndjeka and Edina Sinanovic

Healthcare Finance in the Kingdom of Saudi Arabia: A Qualitative Study of Householders’ Attitudes pp. 55-64

Mohammed Khaled Al-Hanawi, Omar Alsharqi, Saja Almazrou and Kirit Vaidya

Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis pp. 65-77

Paul Barriere, Géraldine Porcu-Buisson and Samir Hamamah

Association Between Medicare’s Mandatory Hospital Value-Based Purchasing Program and Cost Inefficiency pp. 79-90

Germán M. Izón and Chelsea A. Pardini

Comparative Cost-Effectiveness Analysis of Three Different Automated Medication Systems Implemented in a Danish Hospital Setting pp. 91-106

Bettina Wulff Risør, Marianne Lisby and Jan Sørensen

Scale Effects and Expected Savings from Consolidation Policies of Italian Local Healthcare Authorities pp. 107-122

Cinzia Di Novi, Dino Rizzi and Michele Zanette

Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed Expansion pp. 123-132

Thibaut Dort, Nadia Schecroun and Baudouin Standaert

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer pp. 133-143

Michel L. Peters, Claudine Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M. Leliveld-Kors, Joan Bosch, Pieter H. Berg, Agni Baka and Jennifer G. Gaultney

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer pp. 145-145

Michel L. Peters, Claudine Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M. Leliveld-Kors, Joan Bosch, Pieter H. Berg, Agni Baka and Jennifer G. Gaultney